Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications

Canadian Journal of Psychiatry

Volumn 54, Issue 11, 2009, Pages 743-749

  Panagiotopoulos, Constadina ^a,b   Ronsley, Rebecca ^a   Davidson, Jana ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BC CHILDREN S HOSPITAL   (Canada)

Author keywords

Glucose intolerance; Metabolic monitoring; Obesity; Second generation antipsychotics; Youth

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLESTEROL; CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADOLESCENT; ANXIETY DISORDER; ARTICLE; AUTISM; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD PSYCHIATRY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC HYPERTENSION; DISRUPTIVE BEHAVIOR; DYSLIPIDEMIA; EMERGENCY CARE; FEMALE; HUMAN; HYPERTENSION; HYPERTENSTION; IMPAIRED GLUCOSE TOLERANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOOD DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SUBSTANCE ABUSE; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 70449119405     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370905401104     Document Type: Article

References (38)

1. Waddell C, Shepherd C. Prevalence of mental disorders in children and youth [Internet]. Vancouver (BC): The University of British Columbia; 2002 [cited 2009 Oct 14]. Available from: http://www.mcf.gov.bc.ca/mental-health/ mh-publications/02a-cymh.pdf.
2. Doey T, Handelman K, Seabrooke JA, et al. Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Can J Psychiatry. 2007;52:363-368.
3. Cooper WO, Arbogast PG, Ding H, et al. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006;6:79-83.
4. Statistics Canada. BC census data 2002-2006 [Internet]. Ottawa (ON): Statistics Canada; 2008. Available from: http://www.bcstats.gov.bc.ca/census. asp.
5. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain. Drug Saf. 2006;29:303-319.
6. Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf. 2001;24:59-74.
7. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70:1-17.
8. Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical antitpsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology. 2006;186:572-578.
9. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation - evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004;17:173-180.
10. Cohen D. Atypical antipsychotics and new onset diabetes mellitus. Pharmacopsychiatry. 2004;37:1-11.
11. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs. 2002;16:77-89.
12. Jin H, Meyer JM, Jest DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002;14:59-64.
13. Llorente MD, Urritia V. Diabetes, psychiatric disorders, and the metabolic effects of antipsychotic medications. Clin Diabetes. 2006;24:18-24.
14. Alberti KGMM, Zimmet PZ, Shaw JE. The metabolic syndrome in children and adolescents. Lancet. 2007;369:2059-2061.
15. Sicras-Mainar A, Blanca-Tamayo M, Rejas-Gutierrez J, et al. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database. Eur Psychiatry. 2008;23:100-108.
16. Bloomgarden ZT. Atypical antipsychotic agents, retinopathy, nephropathy, and cardiovascular disease. Diabetes Care. 2006;24:1439-1446.
17. Fedorowicz VJ, Fombonne E. Metabolic side effects of atypical antipsychotics in children: a literature review. J Psychopharmacol. 2005;19:533-550.
18. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007;46:687-700.
19. Selva KA, Scott SM. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr. 2001;136:9366-9938.
20. Koller E, Malozowski S. Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA. 2001;286:2547-2548.
21. Weiss R, Caprio S. The metabolic consequences of childhood obesity. Best Pract Res Clin Endocrinol Metab. 2005;19:405-419.
22. US Department of Health and Human Services. 2000 CDC Growth Charts: United States [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2009 [cited 2007 Nov]. Available from: http://www.cdc.gov/ growthcharts.
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2007;30(1):S42-S47.
24. Jolliffe CJ, Janseen I. Distribution of lipoproteins by age and gender in adolescents. Circulation. 2006;114:1056-1062.
25. Falkner B. National high blood pressure education program working group on high blood pressure in children and adolescents: the fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555-576.
26. Tremblay MS, Willms JD. Secular trends in the body mass index of Canadian children. CMAJ. 2000;163:1429-1433.
27. Patel NC, Kistler JS, James EB, et al. A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy. 2004;24:824-830.
28. Fleischhaker C, Heiser P, Hennighausen K, et al. Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm. 2007;114:273-280.
29. Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. 2002;41:337-343.
30. Krekoukia M, Nassis G, Psarra G, et al. Elevated total and central adiposity and low physical activity are associated with insulin resistance in children. Metab Clin Exp. 2007;56:206-213.
31. Fagot-Campagna A, Saaddine JB. Diabetes, impaired fasting glucose, and elevated HbA in US adolescents: the Third National Health and Nutrition Examination Survey. Diabetes Care. 2001;24:834-837.
32. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
33. Yokoyama H, Okudaira M, Otani T, et al. Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care. 1997;20:844-847.
34. Krakoff J, Lindsay RS, Looker HC, et al. Incidence of retinopathy and nephropathy in youth-onset compared with adult onset type 2 diabetes. Diabetes Care. 2003;26:76-81.
35. Eppens MC, Craig ME, Cusumano J, et al. Prevalence of diabetes complications in adolescents with type 2 compared to type 1 diabetes. Diabetes Care. 2006;29:1300-1306.
36. Dolan LM, Bean J, Goodman E, et al. Frequency of abnormal carbohydrate metabolism and diabetes in a population-based screening of adolescents. J Pediatr. 2005;146:751-758.
37. Duncan GE, Li SM, Zhou XH. Prevalence and trends of a metabolic syndrome phenotype among US adolescents, 1999-2000. Diabetes Care. 2004;27:2438-2443.
38. Faraone SV, Biederman J, Morley CP, et al. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(9):994-1009.